Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aranesp Bad Luck Catches Up To Amgen, Forces Pharma-Style Reorganization

Executive Summary

As Amgen enters into a major restructuring effort that will include extensive cost-cutting and significant headcount reductions, it will also make serious adjustments to its R&D program - including scaling back from its industry-leading approach of investing a high percentage of sales on R&D

You may also be interested in...



Nplate REMS Precludes Need For Medicare Coverage Restrictions – Amgen

Amgen's platelet producer Nplate (romiplostim) does not need coverage restrictions from Medicare to ensure its safe use because it is already the subject of an FDA-mandated Risk Evaluation and Mitigation Strategy, the company told CMS in recent comments

Nplate REMS Precludes Need For Medicare Coverage Restrictions – Amgen

Amgen's platelet producer Nplate (romiplostim) does not need coverage restrictions from Medicare to ensure its safe use because it is already the subject of an FDA-mandated Risk Evaluation and Mitigation Strategy, the company told CMS in recent comments

Amgen ESA Sales Dive In The Biotech’s “Toughest” Year

Sales of Amgen's Aranesp and Epogen took a hit in the fourth quarter as the safety of erythropoiesis-stimulating agents was questioned, Amgen reported during its fourth quarter and year-end earnings call Jan. 24. Going into 2008, the company will develop a risk management plan and other strategies to help address the situation

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel